A rapid sensitive and an efficient method development and validation of carfilzomib by UV-Vis spectrophotometric analysis

• Authors: Hayder Naser Hussein , C. T. Pashavan , Ajaykumar Patel , H. S. Joshi
• Languages of publication: EN

Abstracts

EN

People are focusing their attention on personal health in the current situation. Medicine has an important function to play in maintaining our health. Researchers developed various compounds to cure important health issues such as cancer, diabetes, and tuberculosis, among others. We are focusing on Carfilzomib, an anti-cancer drug supplement. The present work discusses the development and validation of the UV Spectrophotometric method for carfilzomib. Simple, specific, and economic purposes UV spectrophotometric method has been developed using the methanol as a diluent to the estimation of carfilzomib in vial formulation. The max of carfilzomib was found to be 203 nm. The linearity in the concentration range 4-16 g/ml was founded to have a good correlation coefficient (R2 = 0.9952). The accuracy was between (99.4-101.2%), The LOD and LOQ are 0.00156 g/ml and 0.00472 g/ml respectively.

Keywords

EN

Anti-cancer; Carfilzomib; Method development; Method validation; UV-Vis

Discipline

• CHEMISTRY: CHEMISTRY

• Publisher: Scientific Publishing House „DARWIN”
• Journal: World Scientific News
• Year: 2022
• Volume: 168
• Pages: 57-68

Contributors

author

Hayder Naser Hussein

• Department of Chemistry, Saurashtra University, Rajkot - 360005, Gujarat, India

author

C. T. Pashavan

• Department of Chemistry, Saurashtra University, Rajkot - 360005, Gujarat, India

author

Ajaykumar Patel

• B. K. Mody Government Pharmacy College, Rajkot - 360005, Gujarat, India

author

H. S. Joshi

• Department of Chemistry, Saurashtra University, Rajkot - 360005, Gujarat, India

References

• [1] Wang, H.; Naghavi, M.; Allen, C.; Barber, R.M.; Bhutta, Z.A.; Carter, A.; Casey, D.C.; Charlson, F.J.; Chen, A.Z.; Coates, M.M. Global, Regional, and National Life Expectancy, All-Cause Mortality, and Cause-Specific Mortality for 249 Causes of Death, 1980–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. The Lancet, 388 (2016) 1459–1544
• [2] Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.; Forman, D.; Bray, F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon. Fr. Internafional Agency Res. Cancer, 2013.
• [3] Shewach, D.S.; Kuchta, R.D. Introduction to Cancer Chemotherapeutics. Chem. Rev. 109 (2009) 2859–2861
• [4] Zahreddine, H.; Borden, K. Mechanisms and Insights into Drug Resistance in Cancer. Front. Pharmacol. 4 (2013) 28
• [5] Min, J.S.; Kim, J.; Kim, J.H.; Kim, D.; Zheng, Y.F.; Park, J.E.; Lee, W.; Bae, S.K. Quantitative Determination of Carfilzomib in Mouse Plasma by Liquid Chromatography–Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study. J. Pharm. Biomed. Anal. 146 (2017) 341–346
• [6] Siegel, D.S.; Martin, T.; Wang, M.; Vij, R.; Jakubowiak, A.J.; Lonial, S.; Trudel, S.; Kukreti, V.; Bahlis, N.; Alsina, M. A Phase 2 Study of Single-Agent Carfilzomib (PX-171-003-A1) in Patients with Relapsed and Refractory Multiple Myeloma. Blood J. Am. Soc. Hematol. 120 (2012) 2817–2825
• [7] Sestak, V.; Roh, J.; Klepalova, L.; Kovarikova, P. A UHPLC-UV-QTOF Study on the Stability of Carfilzomib, a Novel Proteasome Inhibitor. J. Pharm. Biomed. Anal., 124 (2016) 365–373
• [8] Gopireddy, R.R.; Maruthapillai, A.; Devikala, S.; Tamilselvi, M.; Selvi, J.A.; Mahapatra, S. DoE Approach: A Validated Stability Indicating RP-HPLC Method Development for the Separation of Diasteromeric Analogs and Process Impurities of Carfilzomib. 2nd Int. Conf. Recent Adv. Mater. Chem. 14-16 Febr. 14 (2019) 514–531
• [9] Fu, L.; Liu, G.; Zhao, D.; Yuan, L.; Lu, K. Interaction of Two Peptide Drugs with Biomacromolecules Analyzed by Molecular Docking and Multi-Spectroscopic Methods. Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 255 (2021) 119673

• Document Type: article